Personal care or pharmaceutical composition

A composition of vitamin B3 and carboxymethylcysteine at a 6:1 ratio enhances keratinocyte migration, addressing the speed limitations in wound healing and skin regeneration.

JP2024545479APending Publication Date: 2024-12-06UNILEVER IP HLDG BV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024539291
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-01-27
Filing Date
2022-12-12
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing treatments for skin wound healing and regeneration, particularly in terms of keratinocyte migration, are inadequate in terms of speed and efficacy.

Method used

A personal care or pharmaceutical composition comprising a vitamin B3 compound and carboxymethylcysteine compound, with a specific weight ratio of at least 6:1, is applied topically to enhance keratinocyte migration.

Benefits of technology

The composition significantly accelerates keratinocyte migration, thereby improving wound healing and skin regeneration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545479000001
    Figure 2024545479000001
  • Figure 2024545479000002
    Figure 2024545479000002
  • Figure 2024545479000003
    Figure 2024545479000003
Patent Text Reader

Abstract

A personal care or pharmaceutical composition is disclosed comprising a vitamin B3 compound and a carboxymethylcysteine ​​compound, wherein the weight ratio of said vitamin B3 compound to said carboxymethylcysteine ​​compound is at least 6:1.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a personal care or pharmaceutical composition comprising a vitamin B3 compound and a carboxymethylcysteine ​​compound for skin wound healing and / or skin regeneration. [Background technology]

[0002] The skin is the main barrier of the human body, protecting the internal organs from irritation caused by the external environment, such as ultraviolet light, pollutants, and temperature.

[0003] Wound healing is the repair of damaged skin tissue. Delayed or impaired wound healing can cause cosmetic problems or even serious medical conditions such as ulcers. Therefore, treatments that improve wound healing are important for both cosmetic and medical applications. During wound healing, various reactions are involved. Keratinocyte migration is one of the most important processes in wound healing or skin regeneration. Summary of the Invention [Problem to be solved by the invention]

[0004] Therefore, the present inventors have recognized the need to develop a solution to improve the migration rate of keratinocytes for wound healing and / or skin regeneration.Surprisingly, it has been found that the combination of vitamin B3 compounds in a specific weight ratio significantly improves the migration rate of keratinocytes. [Means for solving the problem]

[0005] In a first aspect, the present invention relates to a personal care or pharmaceutical composition comprising a vitamin B3 compound and a carboxymethylcysteine ​​compound, wherein the weight ratio of said vitamin B3 compound to said carboxymethylcysteine ​​compound is at least 6:1.

[0006] In a second aspect, the present invention relates to a method for healing and / or alleviating skin wounds; and / or regenerating skin, comprising topically applying to said skin a composition of the present invention.

[0007] In a third aspect, the present invention relates to the use of a composition of the invention for healing and / or reducing skin wounds; and / or regenerating the skin.

[0008] All other aspects of the present invention will become more readily apparent in light of the following detailed description and examples. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Except in the examples, or where expressly indicated otherwise, all numbers in this description expressing quantities of ingredients or reaction conditions, physical properties of ingredients, and / or uses may be understood to be modified by the word "about."

[0010] Unless otherwise specified, all amounts are by weight of the composition. It should be noted that when specifying a range of values, a particular upper limit can be associated with a particular lower limit.

[0011] For the avoidance of doubt, the word "comprising" is intended to mean "including" but not necessarily "consisting of" or "composed of." In other words, the listed steps or options need not be exhaustive.

[0012] Notwithstanding the fact that the claims may be found without multiple dependency or overlap, the disclosure of the invention found herein should be considered to cover all embodiments found in the claims that are multiple dependent from one another.

[0013] Where a feature is disclosed with respect to a particular embodiment of the invention (e.g., a composition of the invention), such disclosure should be deemed to also apply mutatis mutandis to any other embodiment of the invention (e.g., a method of the invention).

[0014] Vitamin B3 compounds as used herein include niacin, niacinamide, nicotinyl alcohol, derivatives thereof, salts of any of the above, and mixtures thereof. Derivatives typically include nicotinic acid esters, nicotinyl alcohol esters of carboxylic acids, niacinamide N-oxide, nicotinyl amino acids, and / or nicotinic acid n-oxide. Preferably, vitamin B3 compounds include niacin, niacinamide, or mixtures thereof. More preferably, vitamin B3 compounds are selected from niacin, niacinamide, or mixtures thereof. Even more preferably, vitamin B3 compounds include niacinamide, and most preferably, vitamin B3 compounds are niacinamide.

[0015] Preferably, vitamin B3 compound is present in an amount of at least 0.00001% by weight of the composition, more preferably at least 0.0001% by weight, even more preferably at least 0.001% by weight, even more preferably at least 0.01% by weight, and most preferably at least 0.03% by weight. Typically, vitamin B3 compound is present in an amount of 10% by weight or less, preferably 5% by weight or less, more preferably 2% by weight or less, and even more preferably 0.5% by weight or less of the composition. Preferably, niacinamide is present in an amount of at least 0.00001% by weight of the composition, more preferably at least 0.0001% by weight, even more preferably at least 0.001% by weight, even more preferably at least 0.01% by weight, and most preferably at least 0.03% by weight. Typically, niacinamide is present in an amount of 10% by weight or less, preferably 5% by weight or less, more preferably 2% by weight or less, and even more preferably 0.5% by weight or less of the composition.

[0016] The carboxymethylcysteine ​​compound refers to a compound selected from carboxymethylcysteine, a salt of carboxymethylcysteine, an ester of carboxymethylcysteine, an amide of carboxymethylcysteine, or a mixture thereof. Preferably, the carboxymethylcysteine ​​compound comprises carboxymethylcysteine, an ester of carboxymethylcysteine, and / or a salt of carboxymethylcysteine. More preferably, the carboxymethylcysteine ​​compound comprises carboxymethylcysteine ​​and / or a salt of carboxymethylcysteine. Even more preferably, the carboxymethylcysteine ​​compound comprises a salt of carboxymethylcysteine. Even more preferably, the carboxymethylcysteine ​​compound comprises lysine carboxymethylcysteinate, and most preferably, the carboxymethylcysteine ​​compound is lysine carboxymethylcysteinate. Preferably, the carboxymethylcysteine ​​compound is present in an amount of at least 0.00001% by weight of the composition, more preferably at least 0.0001% by weight, even more preferably at least 0.001% by weight, even more preferably at least 0.01% by weight, and most preferably at least 0.1% by weight. Preferably, the carboxymethylcysteine ​​compound is present in an amount of no more than 10% by weight of the composition, more preferably no more than 5% by weight, even more preferably no more than 3% by weight, even more preferably no more than 1% by weight, and most preferably no more than 0.5% by weight.

[0017] Preferably, lysine carboxymethyl cysteinate is present in an amount of 10% or less by weight of the composition, more preferably 5% or less by weight, even more preferably 3% or less by weight, even more preferably 1% or less by weight, and most preferably 0.5% or less by weight. Preferably, lysine carboxymethyl cysteinate is present in an amount of at least 0.00001% by weight of the composition, more preferably at least 0.0001% by weight, even more preferably at least 0.001% by weight, even more preferably at least 0.01% by weight, and most preferably at least 0.1% by weight.

[0018] Preferably, the weight ratio of the vitamin B3 compound to the carboxymethylcysteine ​​compound is 6:1 to 10000:1, more preferably 6:1 to 1000:1, even more preferably 6:1 to 100:1, even more preferably 7:1 to 50:1, and most preferably 8:1 to 20:1. Preferably, the weight ratio of the vitamin B3 compound to the lysine carboxymethylcysteinate is 6:1 to 10000:1, more preferably 6:1 to 1000:1, even more preferably 6:1 to 100:1, even more preferably 7:1 to 50:1, and most preferably 8:1 to 20:1.

[0019] The composition may optionally contain a whitening pigment. The whitening pigment is typically a particle of a high refractive index material. For example, the whitening pigment may have a refractive index greater than 1.3, more preferably greater than 1.8, and most preferably between 2.0 and 2.7. Examples of such whitening pigments include those containing bismuth oxychloride, boron nitride, barium sulfate, mica, silica, titanium dioxide, zirconium oxide, aluminum oxide, zinc oxide, or a combination thereof. More preferred whitening pigments are particles containing titanium dioxide, zinc oxide, zirconium oxide, mica, iron oxide, or a combination thereof. Even more preferred whitening pigments are particles containing zinc oxide, zirconium oxide, titanium dioxide, or a combination thereof, since these materials have particularly high refractive indexes. More preferably, the whitening pigment is selected from titanium dioxide, zinc oxide, or a mixture thereof, and the most preferred whitening pigment is titanium dioxide. The average diameter of the whitening pigment is typically from 15 nm to 1 micron, more preferably from 35 nm to 800 nm, even more preferably from 50 nm to 500 nm, and even more preferably from 100 to 300 nm. The amount of the whitening pigment can be from 0.1 to 15% by weight, preferably from 0.5 to 5% by weight of the composition.

[0020] Preferably, the composition comprises a glutamic acid source selected from the group consisting of glutamine, glutamine esters, glutamic acid, pyroglutamic acid, salts, and mixtures thereof. More preferably, the composition comprises pyroglutamic acid and / or a salt of pyroglutamic acid. Even more preferably, the composition comprises a sodium salt of pyroglutamic acid. Preferably, the glutamic acid source is present in an amount of 0.0001-10% by weight of the composition, more preferably 0.001-6% by weight of the composition, even more preferably 0.01-3% by weight.

[0021] Preferably, the composition comprises a polyhydric alcohol. The polyhydric alcohol may be selected from the group of glycerin, propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol, or mixtures thereof. The most preferred polyhydric alcohol is glycerol, also known as glycerin. The amount of polyhydric alcohol may range from 0.1 to 20% by weight of the composition, preferably from 0.5 to 15% by weight, more preferably from 2 to 10% by weight.

[0022] Preferably, the composition includes an emollient material. Suitable emollient materials include silicones, hydrocarbons, triglycerides, or mixtures thereof. These silicones may be organic, silicone-containing or fluorine-containing, volatile or non-volatile, polar or non-polar. Hydrocarbons may include mineral oil, petrolatum, and polyalphaolefins. Examples of preferred volatile hydrocarbons include polydecanes such as isododecane and isodecane (e.g., Permethyl-99A available from Presperse Inc.) and C7-C8 to C12-C15 isoparaffins (e.g., Isopar series available from Exxon Chemicals). Exemplary triglycerides include, but are not limited to, sunflower seed oil, cottonseed oil, rapeseed oil, soybean oil, castor oil, borage oil, olive oil, shea butter, jojoba oil, and mixtures thereof. Monoglycerides and diglycerides may also be useful. Particularly preferred are glyceryl monostearate and glyceryl distearate.

[0023] Preferably, the composition includes a moisturizer, particularly preferred moisturizers include petrolatum, aquaporin manipulating actives, oat grain flour, substituted ureas such as hydroxyethylurea, hyaluronic acid and / or its precursor N-acetylglucosamine, hyaluronic acid and / or its precursor N-acetylglucosamine, or mixtures thereof.

[0024] Some compositions may include thickeners. These may be selected from cellulose derivatives, natural gums, and acrylic polymers, but are not limited by the type of thickener. Cellulose derivatives include sodium carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, and combinations thereof. Suitable gums include xanthan, pectin, karaya, agar, alginic acid gum, and combinations thereof. Acrylic thickeners include homopolymers and copolymers of acrylic and methacrylic acids, such as carbomers, such as Carbopol 1382, Carbopol 982, Ultrez, Aqua SF-1, and Aqua SF-2, available from Lubrizol Corporation. The amount of thickener may range from 0.01 to 3% by weight of active polymer (excluding solvent or water) in the composition.

[0025] Additionally, the compositions of the present invention may further comprise 0.5-10% by weight of a sequestering agent such as tetrasodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifying and pearlizing agents such as ethylene glycol distearate, titanium dioxide, or Lytron 621 (styrene / acrylate copolymer), all of which are useful for enhancing the appearance and properties of the product.

[0026] The composition may contain water in an amount of from 10 to 96%, more preferably from 26 to 92%, even more preferably from 42 to 88%, and most preferably from 55 to 82% by weight of the composition.

[0027] Preferably, the composition is mixed for about 20 s -1 The composition has a viscosity of at least 10 mPa·s, more preferably in the range of 30 to 10000 mPa·s, even more preferably 50 to 5000 mPa·s, and most preferably 100 to 2000 mPa·s, when measured at a relatively high shear rate of 20° C. Preferably, the composition is in the form of a fluid.

[0028] Preferably, the composition is an emulsion, more preferably an oil-in-water emulsion. Skin care composition refers to a composition suitable for topical application to human skin, including leave-on and wash-off products, but preferably a leave-on composition. The term "leave-on" as used herein with respect to a composition means a composition that is applied or rubbed into the skin and left on. The term "wash-off" as used herein with respect to a composition means a skin cleanser that is applied or rubbed into the skin and is washed off almost immediately after application. Preferably, skin care composition means a flowable liquid, particularly a moisturizer, rather than a makeup product.

[0029] Preferably, the personal care composition is a skin care composition.The term "skin" as used herein includes the skin of the face, neck, chest, abdomen, back, arms, armpits, hands and feet.Preferably, "skin" includes the face and armpits, and more preferably, skin refers to the skin of the face other than the lips and eyelids.

[0030] Preferably, the composition is a topical composition. Preferably, the composition can be in the form of a cream, lotion, ointment, liquid, suspension, emulsion, paste, gel, powder, powder foundation, emulsion foundation, wax foundation, or spray. More preferably, the composition can be formulated in the form of a cream, lotion, ointment, emulsion, gel, or spray.

[0031] The present invention also provides the use of a vitamin B3 compound and a carboxymethylcysteine ​​compound in the manufacture of a medicament for healing and / or alleviating skin wounds and / or regenerating skin, wherein the weight ratio of the vitamin B3 compound to the carboxymethylcysteine ​​compound is at least 6:1.

[0032] Preferably, the use is non-therapeutic. Preferably, the method is non-therapeutic. The term non-therapeutic means that the purpose is typically cosmetic, and not curative or therapeutic.

[0033] The following examples are provided to facilitate understanding of the invention and are not intended to limit the scope of the claims. EXAMPLES

[0034] material

[0035] [Table 1]

[0036] Example 1 This example demonstrates that combinations of vitamin B3 compounds in specific ratios provide improved wound healing effects.

[0037] Migration of epidermal keratinocytes is the basis for skin re-epithelialization during wound healing. The in vitro scrape-wound assay using a monolayer of primary human epidermal keratinocytes is a simple and effective method to assess migration capacity.

[0038] Human epidermal keratinocytes (lot: Ep21012001, Biocell) were cultured at 4.5 × 10 5 Cells / well were seeded in 6-well plates and kept in an incubator at 37°C in 5% carbon dioxide atmosphere in EpiLife™ Keratinocyte medium until the cells reached 70-80% confluency in the wells. The cells were then cultured for 24 hours with fresh medium (as control) or fresh medium supplemented with the various active substances. Wound formation was simulated by scratching the cells with a 5 mL pipette tip in the same way, and the wound was recorded immediately by taking an image of the cells. The cells were again cultured for 24 hours at 37°C with the same fresh medium or fresh medium supplemented with the various active substances, and the cells were again imaged. The area ratios before and after the further culture were obtained using the software Image-pro plus. The relative migration rates for the various active substances were calculated by dividing the control values ​​and are summarized in Table 1.

[0039] Table 1 [Table 2]

[0040] From Table 1, it is clear that the relative migration rate is significantly improved only when niacinamide and lysine carboxymethyl cysteinate are combined in the weight ratio of the present invention (1 vs. C and D). In contrast, when niacinamide and lysine carboxymethyl cysteinate are combined in the weight ratio outside the range of the present invention, the relative migration rate is not significantly improved (F vs. A and E; G vs. A and D; H vs. B and D).

Claims

1. 1. A personal care or pharmaceutical composition comprising a vitamin B3 compound and a carboxymethylcysteine ​​compound, wherein the weight ratio of said vitamin B3 compound to said carboxymethylcysteine ​​compound is at least 6:

1.

2. The composition of claim 1 , wherein the carboxymethylcysteine ​​compound comprises carboxymethylcysteine, an ester of carboxymethylcysteine, and / or a salt of carboxymethylcysteine.

3. 3. The composition of claim 2, wherein the carboxymethylcysteine ​​compound comprises a salt of carboxymethylcysteine, preferably wherein the carboxymethylcysteine ​​compound comprises lysine carboxymethylcysteinate.

4. 10. A composition according to any one of the preceding claims, wherein the carboxymethylcysteine ​​compound is present in an amount of at least 0.00001% and not more than 10% by weight of the composition, preferably the carboxymethylcysteine ​​compound is present in an amount of at least 0.01% and not more than 3% by weight of the composition.

5. 10. A composition according to any one of the preceding claims, wherein the vitamin B3 compound comprises niacin, niacinamide or a mixture thereof, preferably the vitamin B3 compound is niacinamide.

6. 10. A composition according to any one of the preceding claims, wherein the vitamin B3 compound is present in an amount of at least 0.00001% and not more than 10% by weight of the composition, preferably wherein the vitamin B3 compound is present in an amount of at least 0.001% and not more than 5% by weight of the composition.

7. A composition according to any one of the preceding claims, wherein the weight ratio of said vitamin B3 compound to said carboxymethylcysteine ​​compound is from 6:1 to 10000:1, preferably from 6:1 to 100:

1.

8. The composition according to any one of claims 3 to 7, wherein the weight ratio of said vitamin B3 compound to said lysine carboxymethyl cysteinate is from 6:1 to 10000:1, preferably from 7:1 to 50:

1.

9. 10. The composition according to any one of the preceding claims, wherein the composition is an emulsion, preferably an oil-in-water emulsion.

10. A composition according to any one of the preceding claims, wherein the composition comprises water in an amount of from 10 to 96% by weight of the composition, preferably from 42 to 88% by weight of the composition.

11. 10. A composition according to any preceding claim for use in the treatment of skin wounds.

12. 13. A method for healing and / or alleviating skin wounds; and / or regenerating the skin, comprising topically applying to the skin a composition according to any one of the preceding claims.

13. Use of a composition according to any one of claims 1 to 11 for healing and / or alleviating skin wounds; and / or regenerating the skin.

Citation Information

Patent Citations

  • Use of sulfur-functional carboxylic acids for promoting skin exfoliation or stimulating epidermal regeneration

    JP1999501663A

  • cosmetic

    JP2001048773A

  • Crystallization methods and bioavailability

    JP2013519632A

  • Method of promoting healing

    US4725609A

  • Pharmaceutic, dietetic and cosmetic compositions based on thioctic acid and cysteine

    WO2000053176A1